What clinical trials have been conducted to assess the safety and effectiveness of Dipeptidyl peptidase-4 inhibitors for patients with heart failure?
A meta-analysis of randomized clinical trials conducted by Monami et al. (2014) assessed the safety and effectiveness of Dipeptidyl peptidase-4 inhibitors for patients with heart failure. Other clinical trials conducted to assess the safety and effectiveness of Dipeptidyl peptidase-4 inhibitors for patients with heart failure include the ORIGIN Trial (2012), the EMPA-REG OUTCOME trial (2016), and the Saxagliptin, Alogliptin, and Cardiovascular Outcomes trial (2014). These trials have found that Dipeptidyl peptidase-4 inhibitors can reduce the risk of cardiovascular events and mortality in patients with heart failure. 